Publications
283 results found
Nair A, Rodrigues JCL, Hare S, et al., 2020, A British Society of Thoracic Imaging statement: considerations in designing local imaging diagnostic algorithms for the COVID-19 pandemic, CLINICAL RADIOLOGY, Vol: 75, Pages: 329-334, ISSN: 0009-9260
- Author Web Link
- Cite
- Citations: 96
Rodrigues JCL, Hare SS, Edey A, et al., 2020, An update on COVID-19 for the radiologist - A British society of Thoracic Imaging statement, CLINICAL RADIOLOGY, Vol: 75, Pages: 323-325, ISSN: 0009-9260
- Author Web Link
- Cite
- Citations: 141
Hare SS, Rodrigues JCL, Jacob J, et al., 2020, A UK-wide British Society of Thoracic Imaging COVID-19 imaging repository and database: design, rationale and implications for education and research, CLINICAL RADIOLOGY, Vol: 75, Pages: 326-328, ISSN: 0009-9260
- Author Web Link
- Cite
- Citations: 10
Invernizzi R, Barnett J, Rawal B, et al., 2020, Bacterial burden in the lower airways predicts disease progression in idiopathic pulmonary fibrosis and is independent of radiological disease extent, European Respiratory Journal, Vol: 55, Pages: 1-9, ISSN: 0903-1936
Increasing bacterial burden in the lower airways of patients with idiopathic pulmonary fibrosis confers an increased risk of disease progression and mortality. However, it remains unclear whether this increased bacterial burden directly influences progression of fibrosis or simply reflects the magnitude of the underlying disease extent or severity.We prospectively recruited 193 patients who underwent bronchoscopy and received a multidisciplinary diagnosis of idiopathic pulmonary fibrosis. Quantification of the total bacterial burden in bronchoalveolar lavage fluid was performed by 16S rRNA gene qPCR. Imaging was independently evaluated by two readers assigning quantitative scores for extent, severity and topography of radiographic changes and relationship of these features with bacterial burden was assessed.Increased bacterial burden significantly associated with disease progression (hazard ratio 2.1; 95% confidence interval 1.287–3.474; p=0.0028). Multivariate stepwise regression demonstrated no relationship between bacterial burden and radiological features or extent of disease. When specifically considering patients with definite or probable usual interstitial pneumonia there was no difference in bacterial burden between these two groups. Despite a postulated association between pleuroparenchymal fibroelastosis and clinical infection, there was no relationship between either the presence or extent of pleuroparenchymal fibroelastosis and bacterial burden.We demonstrate that bacterial burden in the lower airways is not simply secondary to the extent of the underlying architectural destruction of the lung parenchyma seen in idiopathic pulmonary fibrosis. The independent nature of this association supports a relationship with the underlying pathogenic mechanisms and highlights the urgent need for functional studies.
Koschel D, Flaherty KR, Wells AU, et al., 2020, Nintedanib in patients with chronic fibrosing Interstitial lung diseases with progressive phenotype: the INBUILD trial, Publisher: GEORG THIEME VERLAG KG, Pages: S106-S107, ISSN: 0934-8387
Lopez S, Lim EL, Horswell S, et al., 2020, Interplay between whole-genome doubling and the accumulation of deleterious alterations in cancer evolution, NATURE GENETICS, Vol: 52, Pages: 283-+, ISSN: 1061-4036
- Author Web Link
- Cite
- Citations: 104
Williams A, Kelleher WP, Nicholson AG, et al., 2020, Diffuse granulomatous disease: looking inside and outside the lungs, Thorax, Vol: 75, Pages: 189-191, ISSN: 0040-6376
Kauczor H-U, Baird A-M, Blum TG, et al., 2020, ESR/ERS statement paper on lung cancer screening, EUROPEAN RESPIRATORY JOURNAL, Vol: 55, ISSN: 0903-1936
- Author Web Link
- Cite
- Citations: 71
Yazdani MF, Morris-Rosendahl D, Chen L, et al., 2020, Images of the month 1: Cough before the storm: A case of pulmonary alveolar microlithiasis, Clinical Medicine, Vol: 20, Pages: 110-111, ISSN: 1470-2118
Hall H, Horst C, Dickson J, et al., 2020, SUMMIT study: management of extrapulmonary incidental findings in a lung cancer screening cohort, Publisher: ELSEVIER IRELAND LTD, Pages: S4-S5, ISSN: 0169-5002
Horst C, Dickson J, Tisi S, et al., 2020, SUMMIT study: protocolised management of pulmonary nodules in a lung cancer screening cohort, Publisher: ELSEVIER IRELAND LTD, Pages: S3-S3, ISSN: 0169-5002
- Author Web Link
- Cite
- Citations: 1
Tisi S, Dickson J, Horst C, et al., 2020, SUMMIT study: protocolised management of pulmonary incidental findings in a lung cancer screening cohort, Publisher: ELSEVIER IRELAND LTD, Pages: S5-S5, ISSN: 0169-5002
Bax S, Jacob J, Ahmed R, et al., 2020, Right ventricle to left ventricle ratio at CTPA predicts mortality in interstitial lung disease, Chest, Vol: 157, Pages: 89-98, ISSN: 0012-3692
INTRODUCTION: Patients with interstitial lung disease (ILD) may develop pulmonary hypertension (PH), often disproportionate to ILD severity. Right ventricle to left ventricle diameter ratio (RV:LV) measured at CT pulmonary angiography (CTPA), has been shown to provide valuable information in pulmonary arterial hypertension patients and to predict death or deterioration in acute pulmonary embolism. METHODS: Demographics, ILD subtype, echocardiography and detailed CTPA measurements were collected in consecutive patients undergoing both CTPA and right heart catheterisation (RHC) at the Royal Brompton Hospital between 2005 and 2015. Fibrosis severity was formally scored using CT criteria. RV:LV ratio at CTPA was evaluated by three different methods. Cox-proportional hazard analysis was used to assess the relation of CTPA-derived parameters to predict death or lung transplantation. RESULTS: 92 patients were included: 64% male, mean age 65±11 years, with FVC 57±20% (predicted), TLCOc 22±8% (predicted) and KCOc 51±17% (predicted). PH was confirmed at RHC in 78%. Of all CTPA-derived measures, an RV:LV ratio ≥1.0 strongly predicted mortality or transplantation at univariate analysis (HR 3.26, 95%CI:1.49-7.13, p=0.003), whereas invasive haemodynamic data did not. The RV:LV ratio remained an independent predictor at multivariate analysis (HR: 3.19, CI:1.44-7.10, p=0.004), adjusting for an ILD diagnosis of IPF and CT derived ILD severity. CONCLUSION: An increased RV:LV ratio measured at CTPA provides a simple, non-invasive method of risk stratification in patients with suspected ILD-PH. This should prompt closer follow up, more aggressive treatment and consideration of lung transplantation.
Brown KK, Walsh SLF, Devaraj A, et al., 2020, Does HRCT Pattern Influence the Effect of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases?, Virtual International Conference of the American-Thoracic-Society, Publisher: AMER THORACIC SOC, ISSN: 1073-449X
Bartlett EC, Kemp S, Derbyshire J, et al., 2019, IMPLICATIONS AND OUTCOMES OF CLINICAL AND RADIOLOGICAL INCIDENTAL LUNG CANCER SCREENING FINDINGS FOR PRIMARY CARE - RESULTS FROM A PILOT SCREENING STUDY, Winter Meeting of the British-Thoracic-Society, Publisher: BMJ PUBLISHING GROUP, Pages: A129-A129, ISSN: 0040-6376
Daniels E, Kadwani O, Molyneaux P, et al., 2019, TEMPORALLY CLOSE PRESENTATION OF PRIMARY LUNG CANCER AND IDIOPATHIC PULMONARY FIBROSIS (IPF): AN ANALYSIS OF INCIDENT IPF CASES FROM 2007-2018, Winter Meeting of the British-Thoracic-Society, Publisher: BMJ PUBLISHING GROUP, Pages: A122-A122, ISSN: 0040-6376
Ruparel M, Quaife SL, Dickson JL, et al., 2019, Evaluation of cardiovascular risk in a lung cancer screening cohort, THORAX, Vol: 74, Pages: 1140-1146, ISSN: 0040-6376
- Author Web Link
- Cite
- Citations: 40
Hall H, Ruparel M, Quaife S, et al., 2019, THE ROLE OF COMPUTER-ASSISTED RADIOGRAPHER REPORTING IN LUNG CANCER SCREENING PROGRAMMES, Winter Meeting of the British-Thoracic-Society, Publisher: BMJ PUBLISHING GROUP, Pages: A131-A132, ISSN: 0040-6376
Chua F, Desai SR, Nicholson AG, et al., 2019, Pleuroparenchymal Fibroelastosis A Review of Clinical, Radiological, and Pathological Characteristics, ANNALS OF THE AMERICAN THORACIC SOCIETY, Vol: 16, Pages: 1351-1359, ISSN: 1546-3222
- Author Web Link
- Cite
- Citations: 76
Soo E, Edey AJ, Mak SM, et al., 2019, Impact of choice of volumetry software and nodule management guidelines on recall rates in lung cancer screening, EUROPEAN JOURNAL OF RADIOLOGY, Vol: 120, ISSN: 0720-048X
- Author Web Link
- Cite
- Citations: 15
Flaherty KR, Wells AU, Cottin V, et al., 2019, Nintedanib in progressive Fibrosing interstitial lung diseases, New England Journal of Medicine, Vol: 381, Pages: 1718-1727, ISSN: 0028-4793
BackgroundPreclinical data have suggested that nintedanib, an intracellular inhibitor of tyrosine kinases, inhibits processes involved in the progression of lung fibrosis. Although the efficacy of nintedanib has been shown in idiopathic pulmonary fibrosis, its efficacy across a broad range of fibrosing lung diseases is unknown.MethodsIn this double-blind, placebo-controlled, phase 3 trial conducted in 15 countries, we randomly assigned patients with fibrosing lung disease affecting more than 10% of lung volume on high-resolution computed tomography (CT) to receive nintedanib at a dose of 150 mg twice daily or placebo. All the patients met criteria for progression of interstitial lung disease in the past 24 months despite treatment and had a forced vital capacity (FVC) of at least 45% of the predicted value and a diffusing capacity of the lung for carbon monoxide ranging from 30 to less than 80% of the predicted value. Randomization was stratified according to the fibrotic pattern (a pattern of usual interstitial pneumonia [UIP] or other fibrotic patterns) on high-resolution CT. The primary end point was the annual rate of decline in the FVC, as assessed over a 52-week period. The two primary populations for analysis were the overall population and patients with a UIP-like fibrotic pattern.ResultsA total of 663 patients were treated. In the overall population, the adjusted rate of decline in the FVC was −80.8 ml per year with nintedanib and −187.8 ml per year with placebo, for a between-group difference of 107.0 ml per year (95% confidence interval [CI], 65.4 to 148.5; P<0.001). In patients with a UIP-like fibrotic pattern, the adjusted rate of decline in the FVC was −82.9 ml per year with nintedanib and −211.1 ml per year with placebo, for a difference of 128.2 ml (95% CI, 70.8 to 185.6; P<0.001). Diarrhea was the most common adverse event, as reported in 66.9% and 23.9% of patients treated with nintedanib and placebo, respectively. Abn
Stainer A, Rice A, Devaraj A, et al., 2019, Diffuse alveolar haemorrhage associated with subsequent development of ANCA positivity and emphysema in three young adults, BMC Pulmonary Medicine, Vol: 19, Pages: 1-9, ISSN: 1471-2466
BackgroundDiffuse alveolar haemorrhage (DAH) is characterized by the diffuse accumulation of red blood cells within the alveoli, presence of ground glass opacities and/or consolidation on computed tomography (CT). Aside from identifiable non-immune causes, DAH is classically subdivided into idiopathic (idiopathic pulmonary haemosiderosis, IPH) and autoimmune DAH. Here we describe three cases presenting with recurrent pulmonary haemorrhage, initially classified as IPH, who, several years after first presentation, develop anti myeloperoxidase antibodies (MPO) positivity, emphysema on CT and, in one case, renal involvement.Case presentationPatient 1 was diagnosed with IPH aged 14. Her disease remained poorly controlled despite immunosuppression, although ANCA remained negative over the years. Nineteen years from initial presentation, she developed MPO-ANCA positive antibodies and mild renal impairment. She was treated with Rituximab with good response. From first presentation, the chest CT was consistently characterized by diffuse ground-glass opacities and interlobular septal thickening. Ten years later, cystic opacities consistent with emphysema, with a striking peribronchovascular distribution, developed. Patient 2 was diagnosed with IPH aged 32. He was treated with corticosteroids and methotrexate, with fluctuating response. At 11 years from initial presentation, MPO-ANCA positivity was identified, and emphysema with a peribronchovascular distribution was observed on CT, with subsequent significant increase in extent. Patient 3 was diagnosed with IPH at the age of seven, and had recurrent episodes of haemoptysis of varying degree of severity, treated with intermittent courses of corticosteroids until age 11, when he was intubated due to severe DAH. Eight years after the diagnosis emphysematous changes were noted on CT and MPO-ANCA positivity developed for the first time 11 years after initial diagnosis.ConclusionsWe believe these three cases highlight: 1) th
Devaraj A, Pulzato I, Kemp S, et al., 2019, What Is the Impact of Localised Data When Training Deep Neural Networks for Lung Cancer Prediction?, Publisher: ELSEVIER SCIENCE INC, Pages: S797-S797, ISSN: 1556-0864
Marcus M, Duffy S, Devaraj A, et al., 2019, The UKLS Nodule Risk Model (UKLS-NRM): Utilising Nodule Volumetry, Publisher: ELSEVIER SCIENCE INC, Pages: S529-S529, ISSN: 1556-0864
Janes S, Dickson J, Devaraj A, et al., 2019, Trial in Progress: Cancer Screening Study With or Without Low Dose Lung CT to Validate a Multi-Cancer Early Detection Blood Test, Publisher: ELSEVIER SCIENCE INC, Pages: S523-S523, ISSN: 1556-0864
- Author Web Link
- Cite
- Citations: 1
Barnett J, Pulzato I, Burn T, et al., 2019, Very Rapid Growth of Small Pulmonary Nodules Predicts Benignity, Publisher: ELSEVIER SCIENCE INC, Pages: S528-S528, ISSN: 1556-0864
Bartlett E, Kemp S, Desai S, et al., 2019, Uptake in Lung Cancer Screening - Does CT Location Matter? A Pilot Study Comparison of a Mobile and Hospital Based CT Scanner, Publisher: ELSEVIER SCIENCE INC, Pages: S289-S289, ISSN: 1556-0864
Hastings R, Mahboobani S, Kempny A, et al., 2019, Impact of ILD severity and subtype on outcomes in CTD-associated PAH, International Congress of the European-Respiratory-Society (ERS), Publisher: EUROPEAN RESPIRATORY SOC JOURNALS LTD, ISSN: 0903-1936
Flaherty KR, Wells AU, Cottin V, et al., 2019, Nintedanib in patients with chronic fibrosing interstitial lung diseases with progressive phenotype: the INBUILD trial, International Congress of the European-Respiratory-Society (ERS), Publisher: EUROPEAN RESPIRATORY SOC JOURNALS LTD, ISSN: 0903-1936
- Author Web Link
- Cite
- Citations: 3
Jacob J, Bartholmai BJ, van Moorsel CHM, et al., 2019, Longitudinal prediction of outcome in idiopathic pulmonary fibrosis using automated CT analysis, European Respiratory Journal, Vol: 54, Pages: 1-5, ISSN: 0903-1936
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.